#EGFR

Joshua Bauml, MD

Jbauml

Up next I am going to go through the CodeBreaK100 trial, evaluating AMG510 in patients with KRAS G12C+ NSCLC. I know a lot of people have already gone over these

FCS ProgeriaResearch

beeks1738

The multi-billion dollar ROR1 opportunity that $ONCT is positioned for and $MRK may have missed (a thread) ROR1 is an onco-embryonic protein rarely expressed in normal cells and highly expressed

Matt

MattBiotech

$DMAC -DiaMedica is a very small company focused on developing a recombinant version of KLK1 called DM199 for two very large indications. DM199 is thought to release nitric oxide and

SWARNASHISH CHATTERJEE

SwarnashishC

Biocon:A thread about Business model & Unprecedented growth opportunity in Biologics (1/10)@unseenvalue https://twitter.com/unseenvalue/status/1261704534637805573 Small molecules:FY 20 revenue Rs.2,094 crores (33% contribution), 18% up

Peter Suzman

Biomaven

Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough anemia to treat is around 2.5 million pts in US.

Michael Kronenberg

SubBasepair_Res

Looking into the literature, it seems like specifically targeting CD47 with an active IgG might maximize the ADCC of the IgG relative to other targets. There are 2 reasons for

brendan

brendan_49

Some random facts about $FATE (engineered NK cells) that might be interesting to my $AFMD (mabs w/ affinity to preload NK cells) and $GMDA (proprietary NK cell expansion combined w/

Vivek Subbiah, MD

VivekSubbiah

By popular demand The Top 10 clinical publications in Oncology in 2020 (In no particular order). Some important papers bundled + Additional 5 more papers representing major advances in the

Elle Lett

madblqscientist

Was following and commenting on a tweet thread by the brilliant @statsepi and the topic of "subjective" and "objective" measures came up and it made me want to have a

Marianne Parshley MD

MParshleyMD

Informatics algorithms & POC decision support tools/apps may bias us inadvertently. Been wondering about this.How do we check for bias?⁦@sagar_ankita⁩ ⁦⁦@TLeungMD⁩⁦@meggerber⁩ ⁦@XimenaLevander⁩ ⁦@littleorphannie⁩ 1

Mark Canney

MarkCanney

A brief thread on why we undertook this study looking at duration of proteinuria remission and clinical outcome in IgA nephropathy, published in this month’s issue of @JASN_News https://jasn.asnjournals.org/content/32/2/436 (1/10)

Samira Farouk, MD, MS, FASN

ssfarouk

1/ Another #immunosuppression #tweetorial...spotlight today on #belatacept today How do you say it? @Babybel @MedTweetorials 2/ Belatacept is the FUSION protein that has been the @NKOTB in #kidneytransplant - having

robert rosencrans

rfrosencrans

Friends, especially White friends, in academic medicine wondering what you can do and what issues you can advocate for. A non-comprehensive breakdown by specialty. I remind you that pledging to

Tony Duffy 💙

Existential_Doc

Malignant bowel obstruction: A palliative thread Possibly one of the most complex and challenging presentations in palliative care.Eating, drinking and going to the toilet are habits of a lifetime. Obstruction

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.